Table 3.
Quantitative data on antibiotic prescribing for (presumed) respiratory tract infection in participants admitted to the COVID-19 ward
| All admissions (n = 281) |
Confirmed COVID-19 admissions (n = 203) |
Rejected COVID-19 admissions (n = 78) |
|
|---|---|---|---|
| Total DDD (n, %) | 289.2 (100) | 177.7 (100) | 111.5 (100) |
| Beta-lactam antibiotics, penicillins | 28.3 (9.8) | 24 (13.5) | 4 (3.9) |
| Penicillins with beta-lactamase inhibitor | 182.1 (63.0) | 109.4 (61.6) | 72.7 (65.2) |
| Other beta-lactam antibiotics | 31.5 (10.9) | 26.0 (14.6) | 5.5 (4.9) |
| Sulfonamides and trimethoprim | 4 (1.4) | 4.0 (2.3) | NA |
| Macrolides, lincosamides and streptogramins | 23 (8.0) | 10.5 (5.9) | 12.5 (11.2) |
| Aminoglycosides | 1.8 (0.6) | 1.8 (1.0) | NA |
| Quinolones | 11 (3.8) | 2.0 (1.1) | 9 (8.1) |
| Other antibacterials | 7.5 (2.6) | NA | 7.5 (6.7) |
| DDD/admission | |||
| Total | 1.029 | 0.875 | 1.429 |
| Beta-lactam antibiotics, penicillins | 0.101 | 0.118 | 0.056 |
| Penicillins with beta-lactamase inhibitor | 0.648 | 0.539 | 0.932 |
| Other beta-lactam antibiotics | 0.112 | 0.128 | 0.071 |
| Sulfonamides and trimethoprim | 0.014 | 0.020 | NA |
| Macrolides, lincosamides and streptogramins | 0.082 | 0.052 | 0.160 |
| Aminoglycosides | 0.006 | 0.009 | NA |
| Quinolones | 0.039 | 0.010 | 0.115 |
| Other antibacterials | 0.027 | NA | 0.096 |
| DDD/100 bed days | |||
| Total | 12.317 | 8.921 | 31.232 |
| Beta-lactam antibiotics, penicillins | 1.206 | 1.205 | 1.214 |
| Penicillins with beta-lactamase inhibitor | 7.752 | 5.493 | 20.357 |
| Other beta-lactam antibiotics | 1.341 | 1.305 | 1.541 |
| Sulfonamides and trimethoprim | 0.170 | 0.201 | NA |
| Macrolides, lincosamides and streptogramins | 0.979 | 0.527 | 3.501 |
| Aminoglycosides | 0.077 | 0.090 | NA |
| Quinolones | 0.468 | 0.100 | 2.521 |
| Other antibacterials | 0.319 | NA | 2.101 |
DDD defined daily doses, NA not applicable